Aytu BioPharma's (AYTU) AR101 Gets FDA's Orphan Drug Status

Published on December 9, 2021

The FDA bestows an Orphan Drug designation to Aytu BioPharma's (AYTU) AR101 for the treatment of vascular Ehlers-Danlos Syndrome.

Continue reading on website
Other news

Best Penny Stocks To Buy Now? 10 Short Squeeze Stocks To Watch

December 9, 2021
Looking for potential short squeeze penny stocks? Start by looking at short interest

DXC vs. DT: Which Stock Is the Better Value Option?

December 9, 2021
DXC vs. DT: Which Stock Is the Better Value Option?